Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$296.4m

Xeris Biopharma Holdings Past Earnings Performance

Past criteria checks 0/6

Xeris Biopharma Holdings has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 62.8% per year.

Key information

2.3%

Earnings growth rate

43.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate62.8%
Return on equityn/a
Net Margin-38.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

Revenue & Expenses Breakdown
Beta

How Xeris Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:XERS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23164-6214622
30 Sep 23153-6213421
30 Jun 23134-7113122
31 Mar 23121-7812720
31 Dec 22110-9513621
30 Sep 2299-13315826
30 Jun 2280-13715026
31 Mar 2263-13814327
31 Dec 2150-12311625
30 Sep 2135-949018
30 Jun 2134-847916
31 Mar 2127-807116
31 Dec 2020-917419
30 Sep 2015-1027628
30 Jun 206-1197540
31 Mar 204-1297254
31 Dec 193-1266360
30 Sep 192-1135160
30 Jun 192-954156
31 Mar 192-733045
31 Dec 182-602141
30 Sep 182-491535
30 Jun 182-421330
31 Mar 181-341025
31 Dec 172-27820
31 Dec 161-13410

Quality Earnings: XERS is currently unprofitable.

Growing Profit Margin: XERS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XERS is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare XERS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XERS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).


Return on Equity

High ROE: XERS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.